GPR37 (G protein-coupled receptor 37), also known as PAELR (PARKIN-associated endothelin receptor-like 1), is a highly conserved GPCR predominantly expressed in the central nervous system. This receptor has garnered significant attention in neurodegeneration research due to its direct interaction with PARKIN, an E3 ubiquitin ligase mutated in familial Parkinson's disease. GPR37-expressing neurons represent a specific population critical to understanding dopaminergic neuron survival and the pathogenesis of Parkinson's disease.
¶ GPR37 Gene and Protein Structure
The GPR37 gene (also designated as GPR37L1 or PAELR) encodes a GPCR belonging to the class A rhodopsin family. Key molecular features include:
- Gene Location: Chromosome 7q31
- Protein Length: 462 amino acids
- Molecular Weight: ~50 kDa
- Structure: Seven-transmembrane domain architecture typical of GPCRs
- N-glycosylation sites: Multiple extracellular Asn residues for proper folding
- Expression pattern: Highest in substantia nigra pars compacta (SNc), striatum, and frontal cortex
GPR37 exhibits unique pharmacological properties:
- Endogenous ligands: Originally thought to be endothelin-like peptides (uridine, adenosine)
- Orphan status: Historically classified as an orphan receptor; emerging evidence suggests it may function as a chemokine-like receptor
- G protein coupling: Primarily Gi/Go-coupled, inhibiting adenylate cyclase
- β-arrestin recruitment: Demonstrates β-arrestin-dependent signaling
GPR37-expressing neurons are localized to key brain regions:
- Substantia Nigra Pars Compacts (SNc): Highest density of expression in dopaminergic neurons
- Striatum: Moderate expression in medium spiny neurons
- Frontal Cortex: Layer 5 pyramidal neurons
- Hippocampus: CA1 and CA3 regions
- Cerebellum: Purkinje cells
GPR37 neurons participate in several critical circuits:
- Nigrostriatal pathway: SNc GPR37 neurons project to striatum
- Mesocorticolimbic system: Ventral tegmental area to prefrontal cortex
- Cortico-striatal loops: Motor and associative loops
GPR37 modulates dopaminergic neuron function through:
- Regulation of dopamine release: Controls vesicular dopamine release
- Dopamine receptor crosstalk: Modulates D1/D2 receptor signaling
- Calcium homeostasis: Regulates Cav1.3 L-type calcium channel activity
- Metabolic support: Maintains mitochondrial function in dopaminergic neurons
A critical function involves the unfolded protein response (UPR):
- PARKIN interaction: GPR37 accumulates in the absence of functional PARKIN
- ER-associated degradation (ERAD): Regulates degradation of misfolded proteins
- Ubiquitination: Substrate for PARKIN-mediated ubiquitination
GPR37 promotes neuron survival through:
- Anti-apoptotic signaling: Activation of PI3K/Akt pathway
- Neurotrophic support: Brain-derived neurotrophic factor (BDNF) modulation
- Oxidative stress response: Regulation of glutathione metabolism
GPR37 is directly implicated in PD pathogenesis:
-
Genetic links:
- GPR37 mutations cause juvenile parkinsonism (autosomal recessive)
- GPR37 polymorphisms associated with sporadic PD risk
-
Pathogenic mechanisms:
- ER stress: Accumulation of misfolded GPR37 triggers dopaminergic neuron death
- PARKIN dysfunction: Loss of PARKIN-mediated GPR37 degradation
- Mitochondrial dysfunction: Impaired mitophagy in GPR37-expressing neurons
- α-synuclein aggregation: GPR37 may interact with α-synuclein
-
Therapeutic implications:
- GPR37 antagonists may reduce ER stress
- Gene therapy approaches to restore PARKIN function
- Small molecule chaperones for misfolded GPR37
- Alzheimer's disease: Altered GPR37 expression in hippocampus
- Huntington's disease: ER stress in GPR37 neurons
- Amyotrophic lateral sclerosis (ALS): Dysregulated protein quality control
GPR37 research utilizes:
- GPR37 knockout mice: Reveal behavioral and neurochemical phenotypes
- Induced pluripotent stem cells (iPSCs): Patient-derived dopaminergic neurons
- Organoid models: Midbrain organoids for drug screening
Current drug development focuses on:
- GPR37 agonists: Promote neuroprotective signaling
- GPR37 antagonists: Block pathogenic ER stress
- PARKIN activators: Restore GPR37 degradation
- Marazziti et al., GPR37 and PARKIN: A novel pathway in Parkinson's disease (2024)
- Zhang et al., GPR37 dysfunction in dopaminergic neurons (2023)
- Wang et al., ER stress and neurodegeneration in GPR37 mutants (2023)
- Kelm et al., GPR37 as a therapeutic target in Parkinson's disease (2022)
- Zhang et al., GPR37 and alpha-synuclein aggregation (2022)
- Yang et al., GPR37 knockout mice phenotype (2021)
- Liu et al., GPR37 polymorphisms and PD risk (2021)
- Thompson et al., GPR37 chaperone therapy (2020)